Company ProfilePremium

Daehan New Pharm Co., Ltd.

Company Profile Analysis

Ticker: 054670.KQ대한뉴팜 주식회사

ESOMAR 23 Corporate BadgeISO Certifications Badge
Daehan New Pharm Co., Ltd. - Company showcase

Year Founded & Workforce

1984

368 Employees

Daehan New Pharm Co., Ltd. logo

Daehan New Pharm Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Daehan New Pharm Co., Ltd. Overview

Daehan Nupharm is a Korean mid-sized (중견) specialty pharmaceutical manufacturer. It began in 1984 as an animal-drug and feed-additive maker and has since expanded into human prescription drugs, non-reimbursed "well-being" injectables, oral anti-obesity drugs, animal health, bioprocess media and health functional foods. Revenue has held at about KRW 200bn for four years (FY2025: KRW 202.4bn). The mix in Q1 2026 was human pharmaceuticals 56%, animal health 26%, exports 8% and contract manufacturing/other 10%. The company's differentiating assets are a long-standing injectable franchise (glutathione "Luchion", lyophilized "Liporase"), a well-known appetite-suppressant portfolio, and a dual human/veterinary GMP base in the Hyangnam pharmaceutical complex. That base has just been expanded by a roughly KRW 81bn EU-GMP Annex 1-oriented plant targeting commercial operation in early 2027. The investment case now depends on whether that capacity converts into growth. Against it stand compressed margins, rising CSO commissions, net debt of about KRW 90bn, and a succession process that is still incomplete.


The company's own description

On its website, Daehan Nupharm describes a lineage running "from care to cure." It says it started with animal medicines in 1984 and extended into human medicines, biologics and health functional foods, building on long experience in protecting life and health (company product overview page, 2026). It frames its identity around three core values: People, Principle and Challenge. Its "Core Strategy" has four pillars: talent development, stronger R&D capability, cross-divisional business synergy, and sustainable profitable growth across all businesses (company vision page).

The FY2025 business report classifies the business into four reporting lines:

  • Human pharmaceuticals (인체의약품)

  • Animal pharmaceuticals (동물의약품)

  • Overseas business division (해외사업부)

  • Contract manufacturing and other (수탁·기타)

WISEreport's June 2026 company summary describes the prescription portfolio as concentrated in metabolic diseases and peptic ulcer, with R&D extending into obesity and into dementia and Parkinson's disease (WISEreport company overview, as of 1 June 2026).

Business model and revenue model

DimensionCharacterizationEvidence
Revenue modelAlmost entirely product sales (own-manufactured plus in-licensed or distributed products). Contract manufacturing and other income is about 7% to 10% of revenue. No subscription or meaningful licensing income is disclosedSegment mix (Dailypharm, 10 Jul 2026; butler.works Q2 2026)
Product vs. serviceProduct-based. Services are limited to contract manufacturing (수탁)Same
Manufacturing modelVertically integrated manufacturer of oral solids, injectables (including lyophilized vials and ampoules) and veterinary dosage forms at the Hyangnam complex. It supplements its own line with in-licensed and distributed productsFactory page; history page
Human Rx channelHospitals and clinics through the in-house sales force and, increasingly, contract sales organizations (CSOs). Commissions paid (지급수수료) grew from KRW 20.6bn in FY2022 to KRW 26.9bn (FY2023) and KRW 37.5bn (FY2024), then passed KRW 40bn for the first time in FY2025Dealsite, 21 Aug 2025; Dailypharm, 10 Jul 2026
Self-pay (non-reimbursed) channelClinics using "well-being" injectables (glutathione, vitamins, SAMe, thymosin and similar) and aesthetic productsCompany and press (2018–2026)
OTC and health functional foodsPharmacies (for example, the DiNU Kiup product is supplied to about 22,000 pharmacies), online (DiNU store, Naver live commerce), TV home shopping (CJ Onstyle), and a clinic-exclusive line (Dr. DiNU)Company news, 2025–2026
Animal health channelLivestock farms, distributors and veterinary hospitals (veterinarian-only mall "diange"), plus government procurement (30 products listed for 관납, i.e., public supply)Company product catalog
Export channelDistributors and registrations in Southeast Asia, Latin America, the Middle East, Russia/CIS and Central AsiaMedigate News, 12 May 2022; company news, 7 May 2026
Value-chain positionMid-stream: formulation, manufacturing and marketing of mostly generic, improved-generic and in-licensed products. It is not a discovery-stage innovator, and active ingredients are largely sourced externallyProduct catalog; pipeline page

Customer types and end-markets

End-marketCustomersRepresentative products
Prescription (reimbursed)Clinics, hospitals and long-term care facilitiesCardiovascular (44 SKUs), gastrointestinal (21), endocrine/diabetes (18) products; Rapiduo, Newtozet, NP Dapa, Dapaformin
Obesity (mostly self-pay oral)Obesity and primary-care clinicsPentin (phendimetrazine), Festin and PTM (phentermine), Migbos (miglitol), Campbell Double
Self-pay injectables and aestheticsAesthetic, pain, integrative-oncology and wellness clinicsLuchion inj (glutathione), Liporase inj, NuPN inj, V-Bella inj, Derma Cindella (device)
Livestock and aquacultureCattle, swine, poultry, fish and bee farms; distributors; government procurementGranmectin (ivermectin), Neovitarincal, Cowmix, Super Cow, Neoflo, feed supplements
Companion animalsVeterinary hospitalsDH Fuzol tab, Qvecin inj, D'ange brand
BioprocessCell-culture and biomanufacturing laboratoriesCELRENA, BMPro, BMPro-V, ALyS505NK-EX serum-free media
ConsumersPharmacies, e-commerce, home shoppingDiNU (probiotics, propolis, vitamin C, melatonin, children's growth supplement), Harker Herbals
ExportOverseas distributorsLiporase (lyophilized), Luchion inj, Tambutin tab (historical Russia top-3 listing)

Independent characterization

Daehan Nupharm is best understood as a portfolio of domestic niches, not an R&D-driven pharmaceutical company. Its economic engine has three parts:

  • a self-pay injectable franchise that historically delivered gross margins above 50%;

  • an oral obesity franchise built on older appetite suppressants; and

  • a steady animal-health business that gives counter-cyclical diversification.

The weak spot is the reimbursed generic portfolio. With no distinctive lead product, the company has increasingly relied on CSOs and rising commission rates to win prescriptions. This explains why gross margin fell from 55.7% (FY2016) to 45.6% (FY2025) and why operating margin fell from 16.5% (FY2020) to 5.8% (FY2025).

Two unusual features stand out for a company of its size:

Capital allocation into non-core assets: These include a 10.8% stake in Caspian Sunrise, a Kazakhstan oil and gas company that grew out of a 2007 oil-field investment, and a listed-equity portfolio of SK hynix, Nvidia, Broadcom, Apple, Microsoft, Samsung Biologics, QQQ and SLV positions.

  • Owner-family control (40.5%) combined with a low free-float valuation.

Strategy

Stated strategy themes (company website and management statements, 2023–2026; paraphrased)

  1. Capacity-led growth (Hyangnam Project 1-2-3). Phase 1 was the research building (2023). Phase 2 is the GMP Plant 2 (2025, about KRW 81bn). Phase 3 is an automated warehouse. Management says the plant provides a base for stable supply of high-quality medicines and for export expansion, and has said it will strengthen the sales organization to convert higher output and new products into sales from 2027 (Newspim, 14 May 2026).

  2. R&D upgrade. The pipeline centers on improved new drugs: obesity, hypertension, GERD, hyperlipidemia and central nervous system. The bio research institute works on cell therapy and anti-aging. New R&D leadership was hired in 2025.

  3. Therapeutic-area focus. Metabolic disease (diabetes, dyslipidemia, obesity), gastrointestinal, and expansion into dementia and Parkinson's disease (WISEreport, June 2026).

  4. Divisional synergy. A Future Business Division was created in 2023 to link the human, animal and HFF units (Medigate News, 4 Jan 2023).

  5. Companion-animal growth. D'ange brand, veterinarian-only mall, DH Fuzol, Qvecin, and the Nustem cell-therapy pipeline.

  6. Consumer health. DiNU brand expansion through e-commerce, live commerce, home shopping, pharmacy distribution and a licensed character edition.

  7. Export diversification. Central Asia/CIS, building on Southeast Asian, Middle Eastern and Latin American registrations.

  8. Governance and ESG. An anti-bribery management system (annual board review since 2022), a fair-trade compliance program (disclosures in Jan and Jul 2026), and a KITA ESG A- rating.

Strategic initiatives announced or executed in the last 24 months (Oct 2024 to Oct 2026)

InitiativeDateDetailsStatus
4-week obesity injectable consortiumDec 2024Joint development with Daewoong, Tionlab Therapeutics and Darim Biotech, covering non-clinical work through approvalPreclinical (consortium-level); Daehan's specific role and economics not disclosed
Overseas equity investment5 Mar 2025 (board approval)Target and amount not disclosedExecuted (per board record)
R&D leadership reinforcementH1 2025Gil Young-sik and Park Jung-tae hiredDone
Plant 2 completionAug 2025About KRW 81bn; 1bn+ dosage units of solid-dose capacityValidation and product transfer under way; GMP approval target Aug–Nov 2026
Additional capex2025–2027KRW 15bn for production capacity and buildings, KRW 4.5bn for maintenance (IB Tomato)Planned
DiNU line extensionsDec 2025 to Apr 2026Melatonin, kale, oral probiotics, Kiup Pokémon editionLaunched
New distributed brandApr 2026Harker Herbals (New Zealand)Launched
Central Asia pushApr 2026Tashkent medical expo; Uzbek registrationsOngoing
Companion-animal antibioticJul 2026Qvecin inj (cefovecin)Launched
Sales-force reinforcement2,026Expanding the sales organization ahead of 2027 outputOngoing

Cost programs and medium-term targets

No formal cost-reduction program with quantified targets is disclosed. No medium-term financial guidance (revenue, margin or ROE targets) is publicly disclosed. In 2021 the company referred to a "3-year target" and broad hiring but did not publish numbers (iNews24, 2021). Management's operational targets are:

  • GMP approval of Plant 2 in Aug–Nov 2026;

  • start of the injectable line in early 2027 (January 2027 was the original target); and

  • solid-dose capacity about double FY2024 production for each dosage form (IB Tomato, 3 Sep 2025).

Products & Services

The company's online catalog (October 2026) lists 208 human-medicine SKUs: 154 oral, 43 injectable, 11 other, including 15 flagged as new. It also lists 183 veterinary SKUs: 50 cattle, 48 swine, 18 poultry, 21 aquaculture, 4 apiculture, 12 companion-animal and 30 government-procurement items. Pricing for individual products is not publicly disclosed; reimbursed products follow Korea's national health insurance price list. The tables below cover flagship and recently launched products product by product. Launch years are given where disclosed.

Human pharmaceuticals — prescription and self-pay

ProductComposition / descriptionTherapeutic useTarget customerLaunch / latestSource
Rapiduo tab 10/350 mgRabeprazole (PPI) plus magnesium oxide (antacid). Improved new drug; the company describes it as the first such combination, reaching peak blood levels within about one hourGastroesophageal reflux disease (GERD)GI and primary-care clinicsDec 2023 / Mar 2024Company history; Smart Today, 16 May 2024
NewtozetDyslipidemia fixed-dose combination (exact molecules not specified in sources)DyslipidemiaClinics2,021iNews24 (2021)
Newtomega soft capsuleAtorvastatin plus omega-3 acid ethyl estersDyslipidemia / hypertriglyceridemiaClinicsJun 2023 (planned)Medigate News, 12 May 2023
Migbos FC tabMiglitol; carbohydrate-absorption inhibitor sold under domestic exclusive rightsDiabetes / post-meal glucose control (also used in obesity practice)Clinics2,021iNews24 (2021); Dealsite, 21 Aug 2025
NP Dapa tab 10 mgDapagliflozin genericType 2 diabetesClinics—Company catalog
Dapaformin XR tab 10/500 and 10/1000 mgDapagliflozin plus metformin extended-releaseType 2 diabetesClinics—Company catalog
Campbell Double tabBangpungtongseong-san herbal preparation (CSO commission raised from 45% to 55% in March 2025)Obesity-adjacent / constipation (herbal)Clinics—Dealsite, 21 Aug 2025
PentinPhendimetrazine appetite suppressantObesityObesity clinicsLong-standingDealsite, 21 Jul 2017
FestinPhentermine appetite suppressantObesityObesity clinicsLong-standingDealsite, 21 Jul 2017
PTMPhentermine HClObesityObesity clinicsLong-standingDealsite, 21 Jul 2017
TopinObesity-portfolio brand cited by the company (composition not disclosed in sources)ObesityClinicsLong-standingDealsite, 21 Jul 2017
ZerofatOrlistat, co-marketed with Mothers PharmObesity (fat absorption)Clinics2,017Dealsite, 21 Jul 2017
Luchion injGlutathione injection, widely known in Korea as a "baek-ok" (whitening) shot. Registered in UzbekistanSelf-pay wellness / liver supportAesthetic and wellness clinics; export2,012Dealsite, 14 Nov 2018; company news, 7 May 2026
Luchion tabOral glutathione line extensionWellnessClinics and pharmacies2,020Asia Economy, 11 Nov 2020
Cindella injGlutathione injectionSelf-pay wellnessClinicsMid-2010seToday (2017)
Same injSAMe (ademetionine); licensed for depression and used in liver and pain indicationsSelf-payClinics2,018Edaily (2018); Dealsite, 14 Nov 2018
Thymosin injThymosin; adjunct in cancer careSelf-pay supportive careIntegrative-oncology clinics2,018Edaily (2018)
Liporase injLyophilized injectable; the company's main export productPain treatment (catalog category)Clinics; Southeast Asia, Latin America, Middle East (Iran and Peru registrations, first shipment March 2022)Long-standingCompany catalog; Medigate News, 12 May 2022
NuPN injNew injectable listed under pain treatmentPainClinicsRecent (flagged new)Company catalog
V-Bella injNew injectable (category "other")—ClinicsRecent (flagged new)Company catalog
NP Flu Premix injReady-to-use premixed influenza antiviral injectionInfluenzaHospitals and clinicsSep 2024Finance Scope, 25 Sep 2024
Daehan Nupharm Acetaminophen injIV acetaminophenFever and painHospitalsRecent (flagged new)Company catalog
Arginine Premix injPremixed arginine injectionOtherHospitals and clinicsRecent (flagged new)Company catalog
Pine-S tabBromelainRhinitis / nasal congestionPharmacies and clinics2,020Asia Economy, 11 Nov 2020
Tambutin tabExport product, ranked among Russia's top-3 drugs (2016–2017)—Russian distributorsMid-2010sCompany history page
Distributed vaccines and antitoxinsPit-viper antivenom (described as the only one in Korea), varicella vaccine, live Japanese encephalitis vaccinePrevention and envenomationHospitals and clinics2022–2023Medigate News, 12 May 2023
Legacy reimbursed brandsTertan tab, Amloc tab, Tarocin SR tab, NP Star tab (as listed by Morningstar)Cardiovascular and othersClinicsOlderMorningstar profile

Human medical devices and aesthetics

ProductDescriptionStatusSource
Derma CindellaDevice-classified dermal injectableFlagged newCompany catalog
Vitamin D rapid diagnostic kitPoint-of-care testFlagged newCompany catalog
HA fillers (Qgel, Flore; Plancell)Domestic exclusive for Korea BNC fillers (2017); overseas sales of Estepharm's Plancell (2019)HistoricaleToday (2017); Dealsite, 14 May 2019
Tess Lift SoftPremium mesh-structure absorbable lifting thread, exclusive distribution2,018Dealsite, 14 Nov 2018

Animal health

ProductDescriptionSpeciesLaunchSource
Granmectin pellet / pour-on / Plus pelletIvermectin-based antiparasiticsCattle, swine; government procurementCurrentCompany catalog
Neovitarincal powder / Gold pelletVitamin and mineral supplementCattle, swine, poultryCurrentCompany catalog
Glu-Vitamin Health powderNutritional supplementFishCurrentCompany catalog
Traxx inj (tulathromycin)Treatment for bacterial respiratory disease. Generic entry followed patent expiry in H2 2019; the company said the domestic market grew from about KRW 3bn to about KRW 9bn after expiryCattle and swineApproval targeted 2021; tulathromycin product launched by Q1 2022iNews24 (2021); Medigate News, 12 May 2022
Altrenogest swine hormoneReproductive hormoneSwineH2 2022 (planned)Medigate News, 12 May 2022
PamdizeroStress relieverLivestockH2 2022 (planned)Medigate News, 12 May 2022
Aqua LuchionStress relieverAquacultureH2 2022 (planned)Medigate News, 12 May 2022
Power GABA-CHeat-stress reliefLivestock2,018Edaily (2018)
Chou-yu 99 (colostrum), CustanDisease-prevention feed supplements for gut health and immunityLivestock2,021Asia Economy (2021)
Cowmix, Super Cow, NeofloLivestock products named as key linesCattle and othersLong-standingJobKorea
Starvac, Pigcoc for calves, Ocean DoctorLivestock and aquaculture productsVariousLong-standingMorningstar profile
DH Fuzol tabFluconazole for Malassezia dermatitis; company claims world-first canine fluconazole formulationDogsJun 2024Company history; Smart Today
Qvecin injCefovecin sodium 80 mg/mL; long-acting injectable antibiotic (an ingredient with prior US FDA approval) for skin and urinary-tract infections; prescription veterinary drugDogs and catsJul 2026Company news, 1 Jul 2026
D'angeVeterinary-hospital-exclusive brand and online mallCompanion animalsMay 2022Company history page

Bio products

ProductDescriptionSource
CELRENA (serum-free)Cell-culture mediumMorningstar profile
BMPro / BMPro-V (serum-free)Cell-culture mediaMorningstar profile
ALyS505NK-EX (serum-free)Medium for NK-cell expansionMorningstar profile
Bioprocess materialsSold since 2012; dedicated media plant since 2014Company history page

Health functional foods and consumer

Brand / productDescriptionLaunchSource
DiNU ParaoticsProbiotic using cap-in-cap (capsule-in-capsule) technology, described as a Korean first2,021iNews24 (2021)
DiNU PolisBrazilian green propolis plus vitamin C2,021iNews24 (2021)
DiNU Vitamin C 3 g (DSM ascorbic acid), DiNU Opti-MSMSingle-ingredient supplements2,021iNews24 (2021)
Plant-based Melatonin 5 mg, Organic Curly Kale 100Clean-label lineDec 2025Company news, 12 Dec 2025
DiNU Direct Oral ProbioticsProbiotic for oral healthMar 2026Company news, 25 Mar 2026
DiNU Kiup (Pokémon edition)Children's height-growth supplement using a newly approved individually recognized ingredient (Humulus japonicus extract, HSy2); planned supply to about 22,000 pharmaciesApr 2026Company news, 1 Apr 2026
Dr. DiNUClinic-exclusive supplement brandJan 2023Company history page
Harker Herbals (New Zealand)Distributed natural health brand: Manuka honey lozenges, herbal sticks; CJ home-shopping live broadcastApr 2026Company news, 16 Apr 2026

Financial Narrative

Basis: separate (non-consolidated) K-IFRS statements as reported to DART. FY2021–FY2025 income-statement data are from DART-derived databases (etfshopping/butler.works) and cross-checked against the company IR page for FY2025. Balance-sheet data for FY2024–FY2025 are from the company IR page (quarterly statements). Sources: company IR "재무" and "주요지표" pages (accessed October 2026); etfshopping (DART business reports, FY2016–FY2025); WISEreport (FY2025 EBITDA); Dailypharm, 13 Mar 2026 (debt and cash flow).

Income statement

Diluted EPS is not separately disclosed in the sources reviewed; no dilutive instruments were identified as outstanding. Dailypharm reported FY2021 operating profit as KRW 28.2bn (a record at the time), versus KRW 26.7bn in DART-derived data. The difference may reflect preliminary versus audited figures or a restatement.

Margins and growth (%)

Revenue CAGR FY2021–FY2025 (derived): 5.0%. Nearly all of that growth came in FY2022 (+18.8%). Revenue has been flat at about KRW 202–204bn for FY2023–FY2025.

Quarterly trajectory, Q1 2025 to Q2 2026

Source: company IR page quarterly income statements (FY2025 and FY2026). Q4 2025 net income includes a tax benefit of KRW 2.6bn; FY2025 income tax was a net benefit of KRW 0.3bn.

H1 2026 vs. H1 2025.

The company's own website headline for this release displayed the prior-year amounts (1,017억 revenue, 73억 OP, 55.8억 NI) alongside growth rates that match the H1 2026 figures. The DART-filed numbers above (KRW 110.8bn and so on) are the authoritative series (MediPharm Health News, 14 Aug 2026).

Trailing twelve months to Q2 2026 (derived). Revenue KRW 211.5bn. Operating income KRW 9.7bn (4.6% margin). Net income KRW 23.9bn, inflated by Q2 2026 financial income.

Balance sheet

Sources: company IR page (FY2024–FY2025); Dailypharm, 13 Mar 2026 (FY2023 total borrowings). No goodwill is recognized; the intangibles shown are other intangible assets. Dailypharm puts FY2025 net debt at about KRW 78bn after counting about KRW 1bn of short-term financial instruments as cash-like; FY2024 net debt was KRW 27.9bn on the same basis.

Latest interim balance sheet, 30 June 2026 (KRW bn, company IR page).

Cash flow: notes and sources

Sources: Dailypharm, 13 Mar 2026 (OCF, investing outflow, CIP acquisitions); etfshopping (dividends declared per fiscal year, paid the following April). H1 2025 operating cash flow was −KRW 4.0bn (Dealsite, 22 Aug 2025). Dailypharm (10 Jul 2026) reported a 73% decline in FY2025 operating cash flow.

Returns, leverage and efficiency ratios

Notes: - FY2025 ROE, ROA, interest coverage and asset turnover are company-reported (IR "주요지표" page). FY2024 ROE is derived as net income divided by year-end equity.

  • ROIC (derived) = operating income × (1 − 22% assumed statutory rate) ÷ (equity + net debt) at FY2025 year-end.

  • Interest coverage uses the company's definition. On total finance costs of KRW 3.0bn, operating income covers finance costs only 3.9x. Coverage fell to 4.8x in Q2 2026.

  • CCC (derived): DSO about 70 days (receivable turnover 5.2x) plus DIO about 130 days (average inventory ÷ COGS) minus DPO about 46 days.

  • Inventory turnover of 2.8x (company-reported) indicates a long inventory cycle typical of multi-SKU generic manufacturers.

Commentary on trends, inflections and drivers

Revenue. FY2022 was the inflection year. Revenue jumped 18.8% to KRW 198.0bn on strong human-drug sales: antibiotics and respiratory products during the Omicron wave, injectable growth, and the seasonal obesity business. Animal health also grew, and exports rose with Liporase registrations in Iran and Peru (Medigate News, 12 May 2022). Since then revenue has been flat at about KRW 202bn for three years even though commissions paid to CSOs nearly doubled. Dailypharm (10 Jul 2026) and Dealsite (21 Aug 2025) both argue that the CSO model is buying prescriptions at rising cost without expanding the top line. H1 2026 shows the first meaningful growth in three years (+8.9%), led by all human sub-segments and a higher animal-health share.

Gross margin. The long-run decline from 55.7% (FY2016) to 45.6% (FY2025) and then to 40.9% in Q2 2026 reflects several factors:

  • mix shift away from high-margin self-pay injectables;

  • more distributed and in-licensed products;

  • raw-material cost inflation; and

  • in 2026, cost pressure before the new plant contributes volume.

Management cited cost-of-goods increases in Q1 2026 (WISEreport). Q4 2025 to Q2 2026 gross margins of 41% to 43% are the lowest in the available record.

Operating margin. Margin fell from 16.0% (FY2021) to 5.8% (FY2025) as SG&A rose from KRW 57.3bn to KRW 80.5bn (derived), crossing KRW 80bn for the first time in FY2025 (Dailypharm, 10 Jul 2026). The main drivers were CSO commissions and R&D: research spending rose from KRW 6.3bn (FY2022) to KRW 8.7bn (FY2023), and H1 2025 spending approached the full FY2024 level (IB Tomato, 3 Sep 2025). FY2023 was also hit by the KRW 7.1bn tax assessment, recognized partly through operating results; Dailypharm attributes the 32% FY2023 operating-profit decline to the extra tax and higher R&D.

Net income quality. Reported net income has repeatedly been distorted by one-off items:

  • tax charges: FY2014 KRW 2.8bn, FY2017 KRW 17.2bn, FY2023 KRW 7.1bn;

  • litigation: a provision linked to Lightpharmtech, then about KRW 9bn reversed in Q1 2022;

  • financial income: KRW 13.0bn in Q2 2026, most plausibly valuation or disposal gains on the listed-equity portfolio. This attribution is not confirmed in the sources reviewed; Dealsite (22 Aug 2025) reported the SK hynix position up 169% versus cost.

Operating income is the better measure of core earning power. On that basis TTM earnings are about KRW 9.7bn, roughly one-third of the FY2022 peak.

Balance sheet and cash flow. The Hyangnam Plant 2 investment changed the balance sheet:

  • PP&E rose from KRW 85.0bn to KRW 133.3bn in FY2025 and KRW 138.6bn by June 2026.

  • Total borrowings rose from KRW 36.0bn (FY2023) to KRW 105.6bn (June 2026).

  • FY2025 free cash flow was about −KRW 42.6bn.

  • Operating cash flow was only KRW 5.0bn, as working capital (inventory) absorbed cash and profits fell.

Short-term borrowings plus current long-term debt of KRW 47.5bn exceed cash of KRW 15.3bn about three times over. That makes rollover of bank lines a structural need; the board approved borrowing extensions in January 2024 and January 2025. Leverage is still manageable relative to equity of KRW 149bn, and the listed-equity portfolio and the Caspian Sunrise stake are sources of liquidity that could be sold. IB Tomato (3 Sep 2025) reports a further KRW 15bn of production-capacity and building investment plus KRW 4.5bn of facility maintenance planned through 2027.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsRepresentative products

Human pharmaceuticals (인체의약품)

Domestic prescription (reimbursed) drugs, obesity drugs, self-pay well-being injectables, OTC, medical devices, distributed vaccines

Rapiduo, Newtozet, Migbos, Pentin/Festin, Luchion, Liporase, NuPN, NP Flu Premix

Animal pharmaceuticals (동물의약품)

Livestock, aquaculture and apiculture drugs; feed supplements; companion-animal medicines; government-procurement products

Granmectin, Neovitarincal, Cowmix, Neoflo, DH Fuzol, Qvecin

Overseas business division (해외사업부)

Exports of human (and some veterinary) finished products

Liporase, Luchion inj, Tambutin

Revenue by Segment (%)

Segment (% of revenue)9M2022Q1 2026Q2 2026

Human pharmaceuticals

—56.256

Animal pharmaceuticals

—26.329

Overseas business

6.88.18

Contract manufacturing and other

—9.57

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment (KRW Bn, Derived) Overview

Segment (KRW Bn, derived)H1 2026

Human pharmaceuticals

62.0

Animal pharmaceuticals

32.1

Overseas business

8.9

Contract manufacturing and other

7.8

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

166.6198.0204.2202.2202.4

Gross profit (KRW Bn)

84.090.594.096.992.3

SG&A (KRW Bn, derived = GP − OP)

57.362.975.278.280.5

Operating income (KRW Bn)

26.727.618.818.711.7

EBITDA (KRW Bn)

————16.0

Pre-tax income (KRW Bn)

————15.0

Net income (KRW Bn)

15.724.312.515.515.3

EPS basic (KRW)

1,1181,7338941,1021,087

Dividend per share (KRW)

80100100100100

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue growth (%)

11.618.83.2-1.00.1

Gross margin (%)

50.445.746.047.945.6

Operating margin (%)

16.013.99.29.25.8

EBITDA margin (%)

————7.9

Net margin (%)

9.412.36.17.77.5

SG&A / revenue (%, derived)

34.431.836.838.739.8

Income Statement and Margin Analysis (%)

MetricQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Revenue (KRW Bn)

51.949.948.951.854.856.0

Gross margin (%)

47.647.745.841.442.540.9

Operating income (KRW Bn)

4.23.12.12.33.12.2

Operating margin (%)

8.26.14.34.55.73.8

Finance income (KRW Bn)

0.61.11.52.92.013.0

Net income (KRW Bn)

2.63.02.67.13.011.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Analysis

MetricH1 2025 (KRW Bn)H1 2026 (KRW Bn)Change

Revenue

101.7110.8+8.9%

Operating income

7.35.3−27.6%

Net income

5.614.3+155%

Balance Sheet

MetricFY2023FY2024FY2025

Total assets (KRW Bn)

—221.3270.7

Cash and equivalents (KRW Bn)

—29.720.0

Total borrowings (KRW Bn)

36.058.598.0

Short-term borrowings (KRW Bn)

—39.743.9

Long-term borrowings (KRW Bn)

—18.854.1

Net debt (KRW Bn, derived)

—28.878.0

Total liabilities (KRW Bn)

—95.8130.8

Shareholders' equity (KRW Bn)

—125.4139.9

Property, plant and equipment (KRW Bn)

—85.0133.3

Goodwill and intangibles (KRW Bn)

—1.11.6

Inventories (KRW Bn)

—37.241.1

Trade and other receivables (KRW Bn)

—39.738.4

Working capital (KRW Bn, derived)

—43.542.2

Financial Analysis — Total assets

ItemValue

Total assets

281.4

Cash and equivalents

15.3

Short-term borrowings

46.0

Current portion of long-term debt

1.5

Long-term borrowings

58.1

Total borrowings

105.6

Net debt (derived)

90.4

PP&E

138.6

Total liabilities

132.4

Equity

149.0

Liabilities-to-equity ratio

88.8%

Current ratio

176.7%

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW Bn)

———18.95.0

Capex: construction-in-progress acquisitions (KRW Bn)

————47.6

Investing cash outflow (KRW Bn)

————52.1

Free cash flow (KRW Bn, derived = OCF − capex)

————-42.6

Dividends paid in year (KRW Bn)

01.121.401.401.40

Share buybacks (KRW Bn)

00000

Margin Analysis (%) and Financial Ratios (x)

MetricFY2024FY2025

ROE (%)

12.310.9

ROA (%)

—5.6

ROIC (%, derived)

—4.2

Current ratio (%)

160.5157.9

Borrowings / equity (%)

46.670.0

Liabilities / equity (%)

76.493.5

Net debt / EBITDA (x, derived)

—4.9

Interest coverage (x)

—7.0

Asset turnover (x)

—0.8

Cash conversion cycle (days, derived)

—154

Revenue by Region (%)

Metric9M2022Q1 2026Q2 2026

Overseas share of revenue (%)

6.88.18

Domestic share of revenue (%, derived)

93.291.992

Region / Country Details

Region / countryEvidenceProducts

Southeast Asia

Described as the core export market for Liporase (2022)

Liporase

Latin America (Peru)

Registration completed; first shipment March 2022

Liporase

Middle East (Iran)

Registration completed (2022)

Liporase

Russia

Tambutin among Russia's top-3 drugs in 2016–2017

Tambutin

Uzbekistan / CIS

Products including Luchion inj registered with Uzbek regulators; exhibited at Tashkent medical expo (28–30 Apr 2026)

Luchion inj and others

United States

US customs records show 61 import shipments to the company since 2007, mostly raw materials and feed ingredients (HS 12, 23, 29, 39). These are inbound purchases, not export sales

Panjiva

Capital Markets

ItemValueSource

Last close

KRW 5,440 (20 Oct 2026)

etfshopping

Market capitalization

KRW 78.1bn

etfshopping

52-week range

KRW 5,090 to 7,510 (etfshopping, Oct 2026). Earlier snapshots showed KRW 5,030 to 7,900 (TipRanks, stockhub), reflecting different windows

Sources conflict; both shown

Return, 1 month

−1.1%

etfshopping

Return, 6 months

−23.9%

etfshopping

Return, 1 year

−18.3%

etfshopping

Return, 3 years and 5 years

Reference points: market cap KRW 157.2bn in Aug 2022, KRW 123.2bn in Jan 2023, KRW 107.5bn in Jul 2025 and KRW 78.1bn in Oct 2026, implying a decline of about 50% since Aug 2022 (derived)

Dailypharm; etfshopping

All-time market-cap peak

KRW 271.3bn (28 Feb 2017)

Dailypharm, 6 Jan 2023

Average daily volume

About 30,000 to 32,000 shares (3-month average about 32.2k)

TipRanks

Beta

0.13 (TipRanks)

TipRanks

Buyback authorizations

None in FY2016–FY2025; no buyback or cancellation announced in the last 12 months. Treasury shares about 2.23%

etfshopping; butler.works

Credit ratings (Moody's, S&P, Fitch)

None. The company has no public bonds; domestic bond and CP ratings are blank on WISEreport

WISEreport

Debt maturity profile (30 June 2026)

Due within 12 months: KRW 47.5bn (short-term borrowings KRW 46.0bn plus current long-term debt KRW 1.5bn). Long-term borrowings: KRW 58.1bn. Detailed maturity ladder not publicly disclosed in the sources reviewed

Company IR page

Valuation Multiples

MultipleDaehan NupharmBasis

P/E (FY2025 EPS of KRW 1,087)

5.0x

etfshopping

P/E (TTM EPS of about KRW 1,667, derived)

3.3x

Inflated by Q2 2026 financial income

P/B (FY2025 BPS of KRW 9,971)

0.55x

WISEreport BPS

P/B (June 2026 equity, derived)

about 0.51x

Company IR

EV / EBITDA (FY2025 EBITDA of KRW 16.0bn; EV KRW 168.4bn at June 2026 net debt, derived)

about 10.5x

WISEreport showed 9.07x at an earlier price and on year-end debt

EV / sales (TTM, derived)

about 0.80x

Company IR

Dividend yield

1.85%

etfshopping

Per-Share Data and Dividends & Capital Returns

MetricFY2021FY2022FY2023FY2024FY2025

Dividend per share (KRW)

80100100100100

Total dividends (KRW Bn)

1.121.401.401.401.40

Payout ratio (%)

7.25.811.29.19

Dividend yield at record date (%)

0.71.11.11.4—

Analyst Conclusions

Management guidance

No quantitative revenue or earnings guidance is disclosed. Qualitative guidance:

  • Complete Plant 2 qualification and receive GMP approval (target August to November 2026).

  • Start the injectable lines in early 2027.

  • Strengthen the sales organization to convert higher 2027 output and new products into revenue (Newspim, 14 May 2026).

Consensus expectations

None. There is no sell-side coverage.

Bull case

  1. Capacity-led re-acceleration. H1 2026 revenue grew 8.9% before Plant 2 contributes. If the new lines add own-product volume, exports (Liporase, Luchion, Central Asia) and contract manufacturing from 2027, revenue could break out of the KRW 200bn range, and operating leverage on an SG&A base of about KRW 80bn could restore 10%-plus margins.

  2. Asset backing. At about 0.5x book, with a 10.8% Caspian Sunrise stake and a listed-equity portfolio (Q2 2026 finance income KRW 13.0bn), the market value of KRW 78bn is substantially covered by tangible and financial assets. Monetizing them could cut net debt of about KRW 90bn quickly.

  3. Optionality in obesity and pet health. Participation in a 4-week long-acting obesity injectable consortium, a Phase 3 veterinary cell therapy (Nustem), and new companion-animal antibiotics (Qvecin) and antifungals (DH Fuzol) add low-cost upside that the current multiples do not price.

Bear case

  1. Structural margin decline. Gross margin fell from 47.6% to 40.9% between Q1 2025 and Q2 2026, and operating margin to 3.8%. CSO commissions above KRW 40bn suggest that growth is being bought. Adding Plant 2 depreciation to a stagnant product base could push operating profit close to zero in 2027.

  2. Balance-sheet strain. Borrowings nearly tripled from KRW 36bn (FY2023) to KRW 106bn (June 2026), with about 45% short-term. FY2025 operating cash flow of KRW 5bn did not cover dividends plus maintenance capex. Further capex of about KRW 19.5bn is planned through 2027.

  3. Governance and earnings quality. Recurring tax assessments, net income propped up by securities gains, two amendments of the FY2025 annual filings, a three-person board dominated by the founding family, and succession incentives that may not favor a higher share price before a share gift.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Mid-Nov 2026Q3 2026 report: gross-margin trend, operating cash flow, borrowings, finance income
Aug–Nov 2026 (target)MFDS GMP approval for Plant 2
Early 2027Start of the injectable lines; product-transfer progress; first exports and contract volumes from Plant 2
Mar 2027FY2026 results and dividend; AGM with all director and auditor terms expiring (board-renewal and independence signal)
OngoingAny share gift from the Chairman to the CEO; insider and large-holding filings; changes to the CEO's share pledges
OngoingSales of non-core assets (Caspian Sunrise, listed equities) and use of proceeds
OngoingProgress of the obesity injectable consortium; Nustem Phase 3 readout; new improved-drug approvals (obesity, hypertension, GERD)
OngoingCSO commission trajectory and any regulatory action on the CSO channel

Analyst verdict

Daehan Nupharm is a profitable but stagnating Korean specialty pharmaceutical company at an inflection point it has created itself. For three years the core franchise has produced about KRW 202bn of revenue on steadily falling margins. Operating profit fell from KRW 27.6bn in FY2022 to KRW 11.7bn in FY2025, and further to a TTM figure of about KRW 9.7bn. The causes are structural rather than cyclical: a generic-heavy reimbursed portfolio that depends on rising CSO commissions, a mature appetite-suppressant franchise facing the GLP-1 era, and cost-of-goods pressure that has driven gross margin to the low 40s.

Against this background, management has made the largest bet in the company's history: a roughly KRW 81bn GMP plant designed to EU-GMP Annex 1 standards. The plant doubles solid-dose capacity and adds aseptic lyophilized lines. It is a credible industrial asset. But it was financed largely with debt, net debt is now about KRW 90bn, and its return depends on commercial execution that the company has not yet shown: exports at only about 8% of sales, a thin R&D budget, and no proprietary lead product.

The valuation already reflects much of this skepticism. The shares trade at about 0.5x book, 5x trailing FY2025 earnings and a 1.9% yield, with substantial non-core assets (Caspian Sunrise, listed equities) that could be sold. Governance is the swing factor. Family control at 40.5%, an unresolved succession, pledged CEO shares, a 9% payout and repeated tax and disclosure issues all explain the persistent discount.

On balance, the profile is a deep-value, execution-dependent special situation, not a quality compounder. A re-rating would need three things: GMP approval and visible utilization of Plant 2 in 2027; stabilization of gross margin at 45% or above; and capital-allocation discipline, meaning debt reduction funded by non-core asset sales and a clearer shareholder-return policy. Until those are visible, downside is cushioned by assets, but earnings momentum and governance remain the dominant risks.


APPENDIX — SOURCE LIST AND DATA NOTES

Company sources.

  • dhnp.co.kr: home and updates; history (발자취); factory (공장); R&D pipeline; IR financial statements (재무) and ratios (주요지표) covering FY2024 to Q2 2026; governance overview, board (이사회) and shareholder (주주정보) pages; product catalogs (human and veterinary).

  • Company press releases (2025–2026) on Q1 2026, H1 2026, the ESG rating, DiNU launches, the Tashkent expo and Qvecin.

Regulatory filings (via index and DART-derived databases).

  • DART filing index (IRGO), Nov 2025 to Aug 2026.

  • FY2021–FY2025 business reports (employees, shareholders, executive pay, investees) via etfshopping.com.

  • DART-derived financials via etfshopping.com and butler.works.

  • WISEreport company page (June/July 2026 snapshot, as surfaced in search).

Press.

  • Dailypharm (2022–2026): succession, tax assessments, borrowings, plant, commissions.

  • Dealsite (2017–2025): CSO commissions, equity portfolio, share pledges, Daewoong consortium.

  • IB Tomato (2023, 2025): CEO profile and capex/R&D.

  • Medigate News (2021–2023): litigation, Q1 results, CEO appointment, vaccines.

  • MediPharm Health News (Aug 2025, Aug 2026).

  • Newspim (May 2026); Asia Economy (2020–2021); iNews24 (2021); Edaily (2018, 2022); eToday (2017; Jul 2026 on veterinary GMP reform); KPA News (Feb and Oct 2026); Biotimes; Finance Scope; Smart Today (May 2024); Economist Korea (Jun 2026).

Third-party profiles. Morningstar; TipRanks; PitchBook; TheVC; Panjiva; JobKorea; Jasoseol; Judal; stockhub.

Peer data. butler.works and etfshopping (Huons, Dai Han Pharm, Choongang Vaccine, Eagle Vet); Medigate News and Fintech Times (Huons group FY2025).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NamePositionTerm expiresBackgroundAgeSource

Lee Wan-jin (이완진)

Inside director; Chairman, overall management

18 Mar 2027

Founder; former Representative Director (sole CEO 2020–2022; co-CEO before 2020)

About 75 (reported as 74 in Jul 2025)

Company board page; Dailypharm

Lee Won-seok (이원석)

Inside director; Representative Director and President, head of management

18 Mar 2027

Born 1977. Joined 2004 (some sources say 2005). Worked in the overseas business, finance and management teams; Executive VP of the management division; inside director since 2018; sole CEO since 2 Jan 2023. Created a "Future Business Division" to drive cross-unit synergy

49

Medigate News, 4 Jan 2023; company board page

Jung In-kyung (정인경)

Outside (independent) director

21 Mar 2027

Professor of endocrinology and metabolism, Kyung Hee University Hospital at Gangdong; head of its clinical trial center

—

Company board page

Kwon Oh-kyung (권오경)

Full-time statutory auditor

20 Mar 2027

Former dean of Seoul National University College of Veterinary Medicine; former professor of veterinary orthopedics; former president of the Korean Society of Veterinary Surgery and the Korean Society of Veterinary Clinics

—

Company board page

“—” = not publicly disclosed.

Executive Leadership Team

NameRoleBackgroundSource

Gil Young-sik (길영식)

Managing Director; Head of Central Research Institute (appointed H1 2025)

Head of research at Sam-A Pharm from June 2020

Dailypharm, 22 Jul 2025

Song Young-jun (송영준)

Executive VP; head of synthetic-drug R&D

—

Dailypharm, 22 Jul 2025

Kwon Young-do (권영도)

Head of Bio Research Institute (biologics R&D)

—

Dailypharm, 22 Jul 2025

Park Jung-tae (박정태)

Director; head of scientific/academic development (pharmaceutical development)

Newly recruited in 2025

Dailypharm, 22 Jul 2025

“—” = not publicly disclosed.

Executive Leadership Team (Annual)

NameTitleTotal FY2025 compensation (KRW Bn)

Lee Wan-jin

Chairman

0.90

Lee Won-seok

CEO

0.52

Average per director/auditor (4 persons)

—0.37

Board & Management Changes

DateChange

31 Jan 2020

Co-CEO structure (Lee Young-seop and Lee Wan-jin) replaced by Lee Wan-jin as sole CEO

2 Jan 2023

Lee Won-seok appointed sole Representative Director and President; founder steps down as CEO but remains Chairman

18 Mar 2024

Board resolution on reappointing the CEO and on dismissing and appointing the company's registered manager (지배인)

H1 2025

Gil Young-sik (R&D) and Park Jung-tae (scientific/academic development) recruited

Major Shareholders

HolderRelationshipStake (%)

Lee Wan-jin

Largest shareholder (founder)

26.53

Lee Won-seok

Son (CEO)

7.92

Choi Sung-sook

Spouse

2.46

Avent Korea Co., Ltd.

Related company (effectively controlled by daughter Lee Ji-min)

1.97

Lee Ji-min

Daughter

1.39

Other family members (3)

Daughter-in-law and grandchildren

0.21

Total largest shareholder and related parties

—

40.50

Treasury shares

Company

about 2.23

Minority shareholders (10,916 holders)

—56.87

Competitive Landscape

Competitors by Segment

SegmentCompetitorOverlapComparative scale (FY2025 unless noted)Source

Self-pay injectables / wellness

Huons (243070)

Injectables, well-being and aesthetic injectables, exports

Consolidated revenue KRW 620.8bn; operating profit KRW 45.6bn

Medigate News, 14 Feb 2026

Aesthetics / injectables

Humedix (Huons group)

HA fillers, injectables

Revenue KRW 170.1bn; operating profit KRW 42.3bn

Fintech Times, Feb 2026

Hospital injectables / fluids

Dai Han Pharm (023910)

Hospital injectables (ampoules and vials)

Revenue KRW 208.6bn; operating profit KRW 31.2bn

butler.works

Obesity drugs

Daewoong Pharmaceutical

Obesity (also a consortium partner)

Not compiled in this research

Dealsite, 15 May 2025

Obesity drugs (incretins)

Novo Nordisk (Wegovy), Eli Lilly (Mounjaro)

GLP-1 and GIP/GLP-1 therapies displacing older oral appetite suppressants

Global scale; Lilly's Q1 2026 Mounjaro sales were USD 8.66bn

Economist Korea, Jun 2026

Small/mid generic pharma

Korea Pharma, Dongkoo Bio & Pharma, Shinpoong Pharm, BC World Pharm

Generics and clinic-channel prescriptions

Not compiled in this research

TheVC "similar companies" list

Animal health (vaccines)

Choongang Vaccine Laboratories (072020)

Swine, poultry and companion-animal biologics

Revenue KRW 49.1bn; operating profit KRW 6.5bn

butler.works

Animal health (drugs, exports)

Eagle Vet (044960)

Livestock drugs, feed additives, companion-animal products, EU-GMP veterinary plant

Revenue KRW 43.3bn; operating profit KRW 4.3bn

butler.works

Animal health (other domestic)

Woojin B&G, Daesung Microbiological Labs, Komipharm, Jeil Bio

Livestock biologics and drugs

Not compiled in this research

—

Animal health (multinationals)

Zoetis, MSD Animal Health, Boehringer Ingelheim Animal Health, Elanco (Korean subsidiaries)

Antiparasitics, antibiotics, companion-animal drugs. Zoetis's Convenia is the reference cefovecin product that Qvecin competes with

Global scale

—

Health functional foods

Large domestic HFF players (for example, Korea Ginseng Corp., Chong Kun Dang Health)

Probiotics, vitamins, children's growth supplements

Not compiled in this research

—

Peer Comparison FY2025

MetricDaehan NupharmHuonsDai Han PharmChoongang VaccineEagle Vet

Revenue (KRW Bn)

202.4620.8208.649.143.3

Revenue growth (%)

0.15.22.27.63.9

Operating margin (%)

5.87.315.013.29.9

Market cap (KRW Bn)

78.1267.1159.086.238.8

P/E (x)

5.014.25.810.87.1

P/B (x)

0.560.730.520.800.71

R&D / revenue (%)

3.8————

Company Snapshot

$142.4M

Revenue

368

Employees

1984

Founded

Hwaseong, South Korea

Headquarters

SWOT Analysis

Strengths

  • New, modern capacity: Plant 2: about KRW 81bn, 800m tablets, 200m capsules, 14.4m vials and 21.6m lyophilized vials per year; EU-GMP Annex 1-oriented design (company factory page, 2025)
  • Diversified two-species business: Q1 2026 mix: 56% human, 26% animal, 8% export, 10% contract/other (Dailypharm, 10 Jul 2026)
  • Established self-pay injectable franchise: Luchion inj since 2012; Liporase exported to Southeast Asia, Iran and Peru (Medigate News, 2022)
  • Long record of profitability: Operating profit above KRW 20bn every year from 2018 to 2022; no operating loss in the 10-year record (etfshopping)
  • Liquid non-core assets: 10.8% stake in Caspian Sunrise plus a listed-equity portfolio that produced KRW 13.0bn of finance income in Q2 2026 (company IR; FY2025 investee table)
  • Adequate solvency despite capex: Equity KRW 149.0bn and current ratio 176.7% at June 2026; interest coverage 7.0x in FY2025 (company IR)

Weaknesses

  • Stagnant revenue: KRW 204.2bn, 202.2bn and 202.4bn in FY2023–FY2025 (etfshopping)
  • Persistent margin erosion: Operating margin 16.0% (FY2021) down to 5.8% (FY2025) and 3.8% (Q2 2026); gross margin 40.9% in Q2 2026 (company IR)
  • Dependence on CSO commissions: Commissions rose from KRW 20.6bn (FY2022) to more than KRW 40bn (FY2025), about 20% of revenue (Dealsite; Dailypharm)
  • Recurring tax assessments reduce earnings predictability: KRW 2.8bn (2014), KRW 17.2bn (2017), KRW 7.1bn (2023) (Dailypharm, 2023–2024)
  • Weak cash generation: FY2025 operating cash flow KRW 5.0bn versus KRW 47.6bn capex; derived FCF −KRW 42.6bn (Dailypharm, 13 Mar 2026)
  • Concentrated, family-dominated governance: One outside director among three; family holds 40.5%; Chairman and CEO are father and son (company board page; FY2025 business report)

Opportunities

  • Fill Plant 2 with own products, exports and contract manufacturing: Capacity about double FY2024 output per dosage form (IB Tomato, Sep 2025); management is focused on converting 2027 output into sales (Newspim, May 2026)
  • Exposure to long-acting obesity injectables: 4-week injectable consortium with Daewoong and others (Dealsite, May 2025)
  • Companion-animal growth: DH Fuzol (2024), Qvecin (2026), Nustem in Phase 3 (company pipeline page)
  • Central Asia / CIS exports: Uzbek registrations; Tashkent expo in April 2026 (company news)
  • Veterinary GMP reform may shake out weaker peers: Three-year renewal from 2027; international standards from 2030 starting with injectables (eToday, Jul 2026)
  • Value unlock through capital allocation: P/B about 0.5x; payout only about 9%; non-core holdings could be monetized (etfshopping; investee table)

Threats

  • GLP-1 substitution in obesity: Incretin sales have surpassed leading oncology drugs globally (Economist Korea, Jun 2026); the company's obesity franchise relies on older appetite suppressants
  • Refinancing and interest-rate risk: Short-term debt plus current long-term debt of KRW 47.5bn versus cash of KRW 15.3bn at June 2026 (company IR)
  • Regulatory and compliance risk in the CSO channel: CSO reporting regime since October 2024; commission increases on specific products (Dealsite, Aug 2025)
  • Execution risk on GMP approval and validation: GMP approval targeted Aug–Nov 2026; injectable start slipped from January 2027 to "early 2027" (company factory page; Newspim)
  • Succession-linked share-price dynamics: Press speculation about gifting at low prices; CEO's pledged shares near maintenance levels (Dailypharm, Jul 2025; Dealsite, Aug 2025)
  • Livestock disease and feed-cost cycles hitting animal health: Structural industry exposure, noted for peers such as Eagle Vet (etfshopping peer description)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
12 May 2025Board approves Q1 2025 financial statements: revenue KRW 51.9bn, operating profit KRW 4.2bn Company IR pageLast quarter with an operating margin above 8%
17 Jun 2025Board approves new borrowing Company board pageFunding for Plant 2
22 Jul 2025Gil Young-sik named head of Central Research Institute; Park Jung-tae recruited DailypharmR&D reinforcement tied to the new plant
23 Jul 2025Press reports total borrowings near KRW 70bn, up KRW 32.8bn in a year DailypharmLeverage concern
28 Jul 2025Market cap KRW 107.5bn; speculation about a share gift to the CEO at a low price DailypharmSuccession overhang
1 Aug 2025Plant 2 completion permit Company factory pageCapacity milestone
12 Aug 2025H1 2025: revenue KRW 101.7bn (−0.7%), operating profit KRW 7.3bn (−32%), net income KRW 5.6bn (−48%); operating cash flow −KRW 4.0bn Dailypharm, 18 Aug 2025; DealsiteEarnings trough begins
14 Aug 2025Plant 2 completion announced: about KRW 81bn, 15,150 m², EU-GMP Annex 1-oriented design Dailypharm; Finance ScopeCore growth asset
18 Aug 2025Net debt KRW 63.4bn at H1 end, up KRW 36.4bn in six months DailypharmBalance-sheet stress
19–22 Aug 2025Dealsite series: CSO commission inflation, CEO share-pledge loans near maintenance thresholds, equity-portfolio gainsExposes business-model and governance pressure points
3 Sep 2025IB Tomato: debt exceeds cash; KRW 19.5bn of further capex planned through 2027Funding needs continue
8 Sep 2025Market cap falls below KRW 100bn despite the plant news DailypharmMarket skepticism
18 Sep 2025Board receives ICFR design-evaluation report Company board pageControl environment
11 Nov 2025DiNU live-commerce broadcast with beauty creator Choi Mona on Naver Company newsConsumer brand marketing
13 Nov 2025Q3 2025: revenue KRW 48.9bn, operating profit KRW 2.1bn (−48.8% YoY) Company IR pageMargin low of 4.3%
24 Nov 2025Board approves foreign-currency payment guarantee Company board pageTrade financing for imports
12 Dec 2025DiNU launches plant-based melatonin 5 mg and organic curly kale Company newsClean-label HFF expansion
23 Jan 2026KITA ESG diagnostic grade A- Company newsESG credential
28 Jan 2026Fair-trade compliance program status disclosed IRGO DART indexCompliance
About Feb 2026MFDS periodic GMP inspection of Plant 1: 7 minor ("other") findings; GMP conformity without sanctions KPA NewsQuality-system signal
5 Feb 2026Disclosure of a 30%-plus change in revenue or profit structure (FY2025 operating profit −37.2%) IRGO DART indexConfirms FY2025 earnings decline
11 Mar 2026KRW 100 dividend declared (KRW 1.4bn); AGM convened IRGO; etfshoppingDividend unchanged for a fourth year
13 Mar 2026FY2025 total borrowings KRW 97.9bn (about 8x operating profit); net debt about KRW 78bn DailypharmLeverage peak
18 Mar 2026FY2025 business report and audit report filed (Daeju; unqualified opinion) IRGO; company board pageAnnual filing
25 Mar 2026DiNU Direct Oral Probiotics launch Company newsConsumer health
27 Mar 2026AGM results filed IRGOGovernance
1 Apr 2026DiNU Kiup (Pokémon edition) children's growth supplement for about 22,000 pharmacies Company newsPharmacy-channel push
18 Apr 2026Harker Herbals on CJ home shopping Company newsNew distributed brand
20 Apr 2026FY2025 dividend paid etfshoppingShareholder return
28–30 Apr 2026Tashkent medical expo; Luchion inj and others already registered in Uzbekistan Company news, 7 May 2026Central Asia export push
13–14 May 2026Q1 2026: revenue KRW 54.8bn (+5.8%), operating profit KRW 3.1bn (−26%), net income KRW 3.0bn (+16%); Plant 2 qualification under way Newspim; company newsRevenue growth resumes; margins still falling
19–29 May 2026Large-holding and insider-ownership reports filed IRGO–
1 Jul 2026Qvecin inj launched (long-acting cefovecin antibiotic for dogs and cats) Company newsCompanion-animal portfolio
7 Jul 2026First amendment of the FY2025 business report and audit report IRGO–
10 Jul 2026Press: FY2025 commissions above KRW 40bn for the first time; SG&A above KRW 80bn; Q1 2026 commissions KRW 10.6bn (+7%) DailypharmCSO cost pressure persists
15 Jul 2026Fair-trade compliance program disclosure IRGOCompliance
7 Aug 2026Large-holding report filed IRGO–
14 Aug 2026H1 2026: revenue KRW 110.8bn (+8.9%), operating profit KRW 5.3bn (−27.6%), net income KRW 14.3bn (+155%); Q2 finance income KRW 13.0bn MediPharm Health News; company IR pageGrowth recovery but weaker core profitability
28 Aug 2026Second amendment of the FY2025 business report and audit report IRGODisclosure quality flag
13–20 Oct 2026Shares trade at KRW 5,370–5,440, near the 52-week low; market cap about KRW 77–78bn Judal; etfshoppingValuation at roughly 0.5x book

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment: Human pharmaceuticals was KRW 62,000 Mn in H1 2026.
Daehan New Pharm Co., Ltd. — Revenue by Segment
Series (KRW Mn)H1 2026
Human pharmaceuticals62,000
Animal pharmaceuticals32,100
Overseas business8,900
Contract manufacturing and other7,800

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.